2022
DOI: 10.3390/cancers14041057
|View full text |Cite
|
Sign up to set email alerts
|

Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle

Abstract: Immune checkpoint inhibitors (ICI) prolong the survival in an increasing number of patients affected by several malignancies, but at the cost of new toxicities related to their mechanisms of action, autoimmunity. Endocrine toxicity frequently occurs in patients on ICI, but endocrine dysfunctions differ based on the ICI-subclass, as follows: agents targeting the CTLA4-receptor often induce hypophysitis and rarely thyroid dysfunction, which is the opposite for agents targeting the PD-1/PD-L1 axis. Recently, few … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 81 publications
(245 reference statements)
0
4
0
Order By: Relevance
“…The spectrum of ICI-induced hypothalamus–pituitary autoimmunity includes the anterior hypophysitis, infundibulo-neurohypophysis, panhypophysitis, and hypothalamitis, among which the anterior hypophysitis is the most common entity [ 66 ]. The higher incidence of anterior pituitary deficiency as compared with the rare manifestation of posterior pituitary dysfunction in ICI-induced hypophysitis may be attributed to the rich vascularity of the anterior pituitary gland with higher exposure to systemic therapy and its associated toxicities [ 57 ].…”
Section: Literature Review Resultsmentioning
confidence: 99%
“…The spectrum of ICI-induced hypothalamus–pituitary autoimmunity includes the anterior hypophysitis, infundibulo-neurohypophysis, panhypophysitis, and hypothalamitis, among which the anterior hypophysitis is the most common entity [ 66 ]. The higher incidence of anterior pituitary deficiency as compared with the rare manifestation of posterior pituitary dysfunction in ICI-induced hypophysitis may be attributed to the rich vascularity of the anterior pituitary gland with higher exposure to systemic therapy and its associated toxicities [ 57 ].…”
Section: Literature Review Resultsmentioning
confidence: 99%
“…More records should be screened to further confirm the application value of the trigger. L21 and L22 are mainly used for the adverse events of pituitaritis caused by the new antitumor drug PD-1/PD-L1 preparation, which is a common irAE in patients with cancer treated with PD-1/PD-L1 ( 27 ). The failure to be identified may be related to the insufficient application of PD-1/PD-L1 preparation in our hospital.…”
Section: Discussionmentioning
confidence: 99%
“…An inverse signal indicates may work in an inhibitory manner [38]. Among the pituitary-related adverse events caused by ICIs, diabetes insipidus is rare, occurring only 0.7% of the time, and has been reported to result from panhypopituitarism, a selective injury to the posterior pituitary gland or hypothalamus [39]. The mechanism underlying the higher prevalence of ICI-induced adverse events in the anterior pituitary than in the posterior pituitary or hypothalamus remains unclear.…”
Section: Discussionmentioning
confidence: 99%